1. Introduction
===============

In recent years, there are millions of new cancers and cancer-related deaths all over the world.^\[[@R1]\]^ Cancer is still a leading cause of mortality worldwide.^\[[@R2]\]^ Although we have tried over and over again to search better methods in the diagnosis and therapy, many solid tumors still lack specific tumor biomarkers and effective treatments. Therefore, it is quite necessary to find novel therapeutic approaches and tumor biomarkers with high specificity and sensitivity, especially in the detection of biomarkers and the research of molecular mechanisms.

Nowadays, researches on SRY-related HMG-box gene 2 (SOX2) in tumorigenesis and tumor progression is still attached much attention. As early as in 1990, a gene called sex-determining region Y (SRY) was found to be located on the sex-determining region of the Y chromosome encoding for a new transcription factor with a distinctive DNA-binding domain.^\[[@R3],[@R4]\]^ The SRY protein binds to specific DNA sequences with its high-mobility-group (HMG) domain. The so-called SRY-related HMG box (SOX) proteins contain an HMG domain with at least 50% sequence similarity to the HMG domain of SRY. Among all *SOX* genes, SOX2 is probably the most recognized. SOX2, a gene on chromosome 3q26.3-q27 that encodes a member of the SOX family of transcription factors, which regulate embryonic development and determine cell fate.^\[[@R5]\]^ Recently, more and more evidences have revealed the role of SOX2 to tumorigenesis and suggested many more links between Sox2 and the clinical progression of solid tumors. However, there were no consensuses among them. So making it certain whether SOX2 overexpression is a prognostic marker for unfavorable pathologic features and poor outcomes in human solid tumors is vitally important.

2. Methods
==========

2.1. Literature search strategy
-------------------------------

Electronic databases, including PubMed, EMBASE, and Web of Science, were used to search SOX2 expression and clinical results in solid tumors update to November 2018. The search terms included "SRY-related HMG-box Gene 2" or "SOX2" and "tumor" or "cancer" or "prognosis" or "survival. " Only human studies of solid tumors were accepted. So entries amount to 3318 were identified. We set a inclusion criteria including measuring SOX2 by immunohistochemistry (IHC), publishing in English and survival data for at least 5 years. The relevant studies showed in the list of reference were scanned and there were further analysis on other articles of possible interest. The Cohen\'s kappa coefficient is used to reach an Inter-reviewer agreement. We would go all the way to reach a consensus if there was any disagreement between assessors.

2.2. Study selection
--------------------

A study to be qualified for inclusion in this meta-analysis must meet the following criteria:

1.  measure the expression of SOX2 by IHC in the primary cancer tissue;

2.  investigate the association between SOX2 with patients' prognosis (OS);

3.  have a follow-up period no \>5 years;

4.  only English-language studies were included;

5.  the most complete report or the most recent was included when the same results author reported from the same patient population.

All candidate manuscripts were carefully checked and approved by two independent authors (Wang and Liu). Disagreements on conflicting results were resolved between the two authors to obtain a consensus.

2.3. Data collection process and quality assessment
---------------------------------------------------

There were two investigators (Wang and Liu) assessing all the studies independently including patient number, gender, age or median age, country, cancer type, follow-up duration, cut-off definition, cut-off value for SOX2 positivity, references, HR for OS and with corresponding 95% CIs. The OS data were acquired from the tables or Kaplan--Meier curves which contained the negative and positive groups of SOX2. The studies were entire cohort studies in this meta-analysis. Each publication was scored based on the New-Castle-Ottawa (NOS) system to identify high-quality studies.^\[[@R6]\]^ Each study showed a score ≥6 is able to be methodologically sound. Each item was achieved for a consensus NOS score by discussion.

2.4. Statistical analysis
-------------------------

Data were acquired from the original articles and analyzed by the software of RevMan 5.3. The Mantel--Haenszel random-effect model was used for the weighted and pooled HR estimates, while Cochran\'s *Q* and *I*^2^ statistics were used for the heterogeneity statistics.^\[[@R7],[@R8]\]^ According to the Cochrane Handbook for Systematic Reviews of Interventions, differences appearing in the subgroups were assessed. It was considered statistically significant in the case of two-sided *P* \< .05. Publication bias was estimated qualitatively using funnel plots with the standard error, and evaluated by Begg\'s and Egger\'s test.^\[[@R9]\]^

3. Results
==========

3.1. Search results and study characteristics
---------------------------------------------

Twelve studies with entire 3318 patients were showed in this meta-analysis (Fig. [1](#F1){ref-type="fig"}). The included studies are summarized in Table [1](#T1){ref-type="table"}. Two studies evaluated esophagus cancer,^\[[@R10],[@R11]\]^ two studies evaluated breast cancer,^\[[@R12],[@R13]\]^ two studies evaluated colorectal cancer^\[[@R14],[@R15]\]^ and one each evaluated glioma,^\[[@R16]\]^ gastric cancer,^\[[@R17]\]^ lung cancer,^\[[@R18]\]^ head and neck carcinoma,^\[[@R19]\]^ cervical cancer,^\[[@R20]\]^ laryngeal carcinoma.^\[[@R21]\]^ The studies were performed in five countries(China, UK, Sweden, Netherland, and Korea) and published update to November 2018.
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###### 

Characteristics of the included studies.

![](medi-99-e19604-g002)

3.2. Association of SOX2 with OS
--------------------------------

There were eight studies that reported OS data with multivariate analysis. Relevant results showed that SOX2 overexpression in the tumor tissue of human was associated with survival decreasing on solid tumor patients (HR = 1.51; 95% CI 1.32--1.71, *P* \< .001) (Fig. [2](#F2){ref-type="fig"}). There was no evidence of heterogeneity among the eight studies mentioned (*P* = .77, *I*^2^ = 0%). There were seven studies reporting OS data with univariate analysis. Relevant results showed that SOX2 overexpression in the human tumor tissue was relevant to a decrease in survival among solid tumor patients (HR = 1.66; 95% CI 1.46--1.89, *P* \< .001) (Fig. [3](#F3){ref-type="fig"}). Among the seven studies involved, there was no significant heterogeneity (*P* = .76, *I*^2^ = 0%). Pooled HR for OS according to subgroup analysis included studies are shown in Table [2](#T2){ref-type="table"}. We further conducted a subgroup analysis to assess different cancer types OS data with univariate analysis. As is shown in a stratified analysis on solid tumor type, SOX2 overexpression was connected with negative clinical outcome in digestive system neoplasm (HR = 1.61; 95% CI 1.34--1.94, *P* \< .001) (Fig. [4](#F4){ref-type="fig"}A), others (HR = 2.14; 95% CI 1.51--3.04, *P* \< .001) (Fig. [4](#F4){ref-type="fig"}B). In a stratified analysis of country, SOX2 overexpression was connected with negative clinical outcome in China (HR = 1.75; 95% CI 1.39--2.20, *P* \< .001) (Fig. [5](#F5){ref-type="fig"}A), and others (HR = 1.62; 95%CI 1.38--1.90, *P* \< .001) (Fig. [5](#F5){ref-type="fig"}B). We further conducted a subgroup analysis to assess different cancer types OS data with multivariate analysis. As is shown in a stratified analysis on solid tumor type, SOX2 overexpression was connected with negative clinical outcome in digestive system neoplasm (HR = 1.53; 95% CI 1.28--1.83, *P* \< .001) (Fig. [6](#F6){ref-type="fig"}A), others (HR = 1.48; 95% CI 1.23--1.79, *P* \< .001) (Fig. [6](#F6){ref-type="fig"}B). In a stratified analysis of country, SOX2 overexpression was connected with negative clinical outcome in China (HR = 1.60; 95% CI 1.27--2.01, *P* \< .001) (Fig. [7](#F7){ref-type="fig"}A), and others (HR = 1.46; 95%CI 1.25--1.71, *P* \< .001) (Fig. [7](#F7){ref-type="fig"}B). In a stratified analysis of ethnicity, SOX2 overexpression was connected with negative clinical outcome in Asian (HR = 1.54; 95% CI 1.29--1.84, *P* \< .001) (Fig. [8](#F8){ref-type="fig"}A), and others (HR = 1.47; 95%CI 1.22--1.78, *P* \< .001) (Fig. [8](#F8){ref-type="fig"}B).
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Pooled HR for OS according to subgroup analysis.
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3.3. Publication bias
---------------------

The funnel plots presented no evidence of publication bias in the studies of outcome. No evidence for significant publication bias was found in OS with univariate (Fig. [9](#F9){ref-type="fig"}A) and multivariate analysis (Fig. [9](#F9){ref-type="fig"}B).

![Begg\'s funnel plot estimated the publication bias of the included literature for OS with univariate analysis (A) and multivariate analysis (B).](medi-99-e19604-g011){#F9}

4. Discussion
=============

Identifying new biomarkers for better clinical decisions and treatments is under rigorous demand. As a common gene who have been investigated extensively among almost all cancers, SOX2 still plays an uncertain role. So correlation studies from published literatures are systematically evaluated between SOX2 and human solid tumors. This meta-analysis may be the first systematic review to investigate the relevant OS when SOX2 overexpressed in solid tumors. Survival data for 3318 solid tumor patients in 12 different studies were analyzed. In this meta-analysis, the overexpression of SOX2 was a biomarker leading to poor prognosis in human solid tumors, with similar OS results with multivariate analysis and univariate analysis. Concerning solid tumor sites, high SOX2 expression was associated with poor OS in digestive system neoplasms and other system neoplasms. In summary, these findings showed that high SOX2 expression is correlated with poor survival in solid tumors. Further studies are required to verify the potential mechanism and impact of SOX2 in the pathogenesis of human solid tumors in addition to its value in prognosis.

SOX2 expression is associated with adverse outcomes in various human solid tumors including esophagus cancer, breast cancer, lung cancer, gastric cancer, colorectal carcinoma, glioma, head and neck carcinoma, cervical cancer, and laryngeal carcinoma, which indicating that SOX2 may be used as a new tumor biomarker in potential clinical application.

However, there are some limitations in this meta-analysis. First, although the results show no significant publication bias, there are a few small sample studies have not been published or the author has not included in the data which may cause bias. So there was a risk of publication bias. Second, there may be inconsistent data in the included reports, as they used different cut-off values and analytical methods for evaluating SOX2 overexpression. Finally, it may not be completely interpreted for substantial heterogeneity among studies although appropriate analytical methods with random effects-models were used.

In summary, towards the case of most human solid tumors, this meta-analysis makes it clear that SOX2 overexpression is related to poor OS. It also suggests that SOX2 is both a new prognostic indicator and a therapeutic target for human solid tumors.
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